Day: April 19, 2017

Posted on

AbbVie $ABBV says Study did not meet its end result

AbbVie announced that two Phase 3 studies evaluating #veliparib did not meet their primary endpoints. The studies evaluated veliparib in combination with the chemotherapy regimen carboplatin and paclitaxel in patients with squamous non-small cell lung cancer and triple negative breast cancer.

Full results will be presented at upcoming medical meetings or published in a peer-reviewed journal. “Research shows there is a role for PARP inhibitors in cancers associated with DNA repair deficits, such as those with BRCA mutations.

In these clinical trials, we wanted to explore whether a PA527178_434502233267150_400064991_nRP inhibitor could augment chemotherapy in patients with squamous non-small cell lung cancer and triple negative breast cancer by disrupting the repair of cancer cells,” said Gary Gordon, M.D., Ph.D., vice president, oncology clinical development, AbbVie. “Unfortunately, these data do not support the use of veliparib in combination with chemotherapy in these patients.”

For more information, see Stockwinners.

Posted on

Pfizer receives grand jury subpoenas from DOJ

Pfizer $PFE confirmed that the company had received grand jury subpoenas from the U.S. Justice Department as part of an antitrust investigation focused onpfizer-logo intravenous saline solution makers, said Reuters.

Note that in a regulatory filing last night, ICU Medical $ICUI disclosed that on April 18, in connection with the Hospira Infusion Systems business that the company acquired in February 2017 from Pfizer.

See Stockwinners.com to read more.

ICU Medical received a grand jury subpoena issued by the U.S. District Court for the Eastern District of Pennsylvania, in connection with an investigation by the U.S. Department of Justice, Antitrust Division.

See Stockwinners for additional information

Posted on

Oppenheimer bullish on Visa, MasterCard ahead of results

cropped-527178_434502233267150_400064991_n.jpg

The analyst is encouraged by “solid” January intra-quarter volume growth, improving gas price trends, strong retail sales growth, and broadly positive card issuer trends.

Further, Greene continues to believe that MasterCard and Visa are attractive at current levels, given their defensible market positions and strong long-term prospects. Nonetheless, he prefers Visa relative to MasterCard at present given the continuing U.S. volume boost from the Costco $COST wins and JPMorgan Chase $JPM Sapphire Reserve momentum, apparent conservative guidance, and Visa Europe accretion benefits.

See Stockwinners.com to read more.

Translate »